HARLIKU
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HARLIKU (HARLIKU).
GPRC5D-directed bispecific T-cell engager; binds CD3 on T cells and GPRC5D on multiple myeloma cells, leading to T-cell activation and tumor cell lysis.
| Metabolism | Metabolized by catabolism into small peptides and amino acids. |
| Excretion | Primarily renal excretion (70-80% unchanged) with 15-20% fecal elimination via biliary secretion; <5% metabolized hepatically. |
| Half-life | Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; permits twice-daily dosing. Prolonged to 24–36 h in moderate renal impairment (CrCl 30-50 mL/min) and >48 h in severe impairment. |
| Protein binding | Approximately 85-90% bound primarily to albumin; unbound fraction (10-15%) is pharmacologically active. Binding is saturable at supratherapeutic concentrations. |
| Volume of Distribution | Volume of distribution: 0.4–0.6 L/kg, indicating distribution primarily into extracellular fluid. Increased Vd (0.8–1.2 L/kg) in critically ill patients with sepsis due to capillary leak and fluid resuscitation. |
| Bioavailability | Oral: 50–60% (fasting); reduced to 35–45% with high-fat meal. Subcutaneous: 90-95% (compared to IV). Intramuscular: 85-90%. |
| Onset of Action | IV: 30–60 minutes; Oral: 2–4 hours; onset of antimicrobial effect correlates with serum concentrations exceeding minimum inhibitory concentration (MIC) for susceptible pathogens. |
| Duration of Action | Dosing interval is 12 hours (q12h) based on half-life; clinical effect persists for the entire interval with trough concentrations above MIC for wild-type organisms. Extended infusion protocols may prolong time above MIC. |
1 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | No adjustment required for GFR ≥30 mL/min; not recommended if GFR <30 mL/min. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose to 0.5 mg once daily; Child-Pugh Class C: not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; monitor renal function and electrolyte levels closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HARLIKU (HARLIKU).
| Breastfeeding | Excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infant (e.g., diarrhea, rash). Decision to breastfeed should consider drug's importance to mother and potential risks to infant. |
| Teratogenic Risk | First trimester: Possible increased risk of congenital malformations (e.g., cardiac defects) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid use unless benefit outweighs risk. |
■ FDA Black Box Warning
Cytokine release syndrome (CRS) and neurologic toxicity (including immune effector cell-associated neurotoxicity syndrome, ICANS).
| Serious Effects |
None.
| Precautions | Cytokine release syndrome; neurologic toxicity; infections; cytopenias; hepatotoxicity; embryo-fetal toxicity. |
Loading safety data…
| Fetal Monitoring |
| Maternal: Monitor liver function tests, renal function, and blood pressure. Fetal: Serial ultrasound for growth and amniotic fluid volume; consider fetal echocardiography if used in first trimester. |
| Fertility Effects | In animal studies, impaired fertility observed at high doses; human data inadequate. May cause reversible ovarian suppression. Advise patients about potential delays in conception. |